The co‐injected TPCs were located in the periphery of tumor vessels and played a dominant role at the endpoint (Figure S16, Supporting Information), and TCAF2 in TPCs had negligible effects on MVD, vascular size (Figure S17A, Supporting Information), pericyte coverage (Figure S17B, Supporting Information), the integrity of vascular basement membrane (Figure S17C, Supporting Information), and tumor hypoxia (Figure S18, Supporting Information) in orthotopic xenografts. Here, TCAF2 is linked to neoplasm.